Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Halia Therapeutics

Tracked across 3 events · 19 articles · First seen May 12, 2026 · Last active Jun 29, 2026

Sentiment
68
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Halia Therapeutics announced positive final Phase 2 results for its drug ofirnoflast (HT-6184) in lower-risk myelodysplastic syndrome (LR-MDS) and appointed Win Myint as Chief Medical Officer, strengthening its clinical development capabilities.
May 12, 2026 · 6 articles
6 75
Regulatory
Impact: Halia Therapeutics received Fast Track designation for its drug ofirnoflast (HT-6184), which is a significant milestone that will expedite the development and review process, potentially leading to earlier market entry and increased revenue.
Jun 15, 2026 · 7 articles
6 60
Tech
Impact: Halia Therapeutics is a US-based biotechnology company that developed HT-4253, the investigational therapy being evaluated in the trial. The company has also established a new office in Abu Dhabi.
Jun 29, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Halia Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.